Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogen...

Descripción completa

Detalles Bibliográficos
Autores principales: de Haan, Jorine, van Thienen, Johannes V., Casaer, Michael, Hannivoort, Rebekka A., Van Calsteren, Kristel, van Tuyl, Minke, van Gerwen, Mathilde M., Debeer, Anne, Amant, Frédéric, Painter, Rebecca C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869570/
https://www.ncbi.nlm.nih.gov/pubmed/29606950
http://dx.doi.org/10.1159/000487128
_version_ 1783309308448997376
author de Haan, Jorine
van Thienen, Johannes V.
Casaer, Michael
Hannivoort, Rebekka A.
Van Calsteren, Kristel
van Tuyl, Minke
van Gerwen, Mathilde M.
Debeer, Anne
Amant, Frédéric
Painter, Rebecca C.
author_facet de Haan, Jorine
van Thienen, Johannes V.
Casaer, Michael
Hannivoort, Rebekka A.
Van Calsteren, Kristel
van Tuyl, Minke
van Gerwen, Mathilde M.
Debeer, Anne
Amant, Frédéric
Painter, Rebecca C.
author_sort de Haan, Jorine
collection PubMed
description Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
format Online
Article
Text
id pubmed-5869570
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-58695702018-03-30 Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma de Haan, Jorine van Thienen, Johannes V. Casaer, Michael Hannivoort, Rebekka A. Van Calsteren, Kristel van Tuyl, Minke van Gerwen, Mathilde M. Debeer, Anne Amant, Frédéric Painter, Rebecca C. Case Rep Oncol Case Report Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction. S. Karger AG 2018-02-15 /pmc/articles/PMC5869570/ /pubmed/29606950 http://dx.doi.org/10.1159/000487128 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
de Haan, Jorine
van Thienen, Johannes V.
Casaer, Michael
Hannivoort, Rebekka A.
Van Calsteren, Kristel
van Tuyl, Minke
van Gerwen, Mathilde M.
Debeer, Anne
Amant, Frédéric
Painter, Rebecca C.
Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
title Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
title_full Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
title_fullStr Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
title_full_unstemmed Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
title_short Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
title_sort severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869570/
https://www.ncbi.nlm.nih.gov/pubmed/29606950
http://dx.doi.org/10.1159/000487128
work_keys_str_mv AT dehaanjorine severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT vanthienenjohannesv severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT casaermichael severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT hannivoortrebekkaa severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT vancalsterenkristel severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT vantuylminke severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT vangerwenmathildem severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT debeeranne severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT amantfrederic severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma
AT painterrebeccac severeadversereactiontovemurafenibinapregnantwomanwithmetastaticmelanoma

Ejemplares similares